These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17158915)

  • 1. Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy.
    Sciorati C; Galvez BG; Brunelli S; Tagliafico E; Ferrari S; Cossu G; Clementi E
    J Cell Sci; 2006 Dec; 119(Pt 24):5114-23. PubMed ID: 17158915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts.
    Sampaolesi M; Torrente Y; Innocenzi A; Tonlorenzi R; D'Antona G; Pellegrino MA; Barresi R; Bresolin N; De Angelis MG; Campbell KP; Bottinelli R; Cossu G
    Science; 2003 Jul; 301(5632):487-92. PubMed ID: 12855815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability.
    Galvez BG; Sampaolesi M; Brunelli S; Covarello D; Gavina M; Rossi B; Constantin G; Torrente Y; Cossu G
    J Cell Biol; 2006 Jul; 174(2):231-43. PubMed ID: 16831885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice.
    Guttinger M; Tafi E; Battaglia M; Coletta M; Cossu G
    Exp Cell Res; 2006 Nov; 312(19):3872-9. PubMed ID: 16982052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Globular adiponectin as a complete mesoangioblast regulator: role in proliferation, survival, motility, and skeletal muscle differentiation.
    Fiaschi T; Tedesco FS; Giannoni E; Diaz-Manera J; Parri M; Cossu G; Chiarugi P
    Mol Biol Cell; 2010 Mar; 21(6):848-59. PubMed ID: 20089845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress preconditioning of mouse perivascular myogenic progenitors selects a subpopulation of cells with a distinct survival advantage in vitro and in vivo.
    Gargioli C; Turturici G; Barreca MM; Spinello W; Fuoco C; Testa S; Feo S; Cannata SM; Cossu G; Sconzo G; Geraci F
    Cell Death Dis; 2018 Jan; 9(1):1. PubMed ID: 29298988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy.
    Durbeej M; Sawatzki SM; Barresi R; Schmainda KM; Allamand V; Michele DE; Campbell KP
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8910-5. PubMed ID: 12851463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.
    Brunelli S; Sciorati C; D'Antona G; Innocenzi A; Covarello D; Galvez BG; Perrotta C; Monopoli A; Sanvito F; Bottinelli R; Ongini E; Cossu G; Clementi E
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):264-9. PubMed ID: 17182743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necdin enhances muscle reconstitution of dystrophic muscle by vessel-associated progenitors, by promoting cell survival and myogenic differentiation.
    Pessina P; Conti V; Tonlorenzi R; Touvier T; Meneveri R; Cossu G; Brunelli S
    Cell Death Differ; 2012 May; 19(5):827-38. PubMed ID: 22095287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP.
    Buono R; Vantaggiato C; Pisa V; Azzoni E; Bassi MT; Brunelli S; Sciorati C; Clementi E
    Stem Cells; 2012 Feb; 30(2):197-209. PubMed ID: 22084027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle differentiation of embryonic mesoangioblasts requires pax3 activity.
    Messina G; Sirabella D; Monteverde S; Galvez BG; Tonlorenzi R; Schnapp E; De Angelis L; Brunelli S; Relaix F; Buckingham M; Cossu G
    Stem Cells; 2009 Jan; 27(1):157-64. PubMed ID: 18845762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane.
    De Bari C; Dell'Accio F; Vandenabeele F; Vermeesch JR; Raymackers JM; Luyten FP
    J Cell Biol; 2003 Mar; 160(6):909-18. PubMed ID: 12629053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.
    Sciorati C; Buono R; Azzoni E; Casati S; Ciuffreda P; D'Angelo G; Cattaneo D; Brunelli S; Clementi E
    Br J Pharmacol; 2010 Jul; 160(6):1550-60. PubMed ID: 20590643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy.
    Tedesco FS; Gerli MF; Perani L; Benedetti S; Ungaro F; Cassano M; Antonini S; Tagliafico E; Artusi V; Longa E; Tonlorenzi R; Ragazzi M; Calderazzi G; Hoshiya H; Cappellari O; Mora M; Schoser B; Schneiderat P; Oshimura M; Bottinelli R; Sampaolesi M; Torrente Y; Broccoli V; Cossu G
    Sci Transl Med; 2012 Jun; 4(140):140ra89. PubMed ID: 22745439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy.
    Berry SE; Liu J; Chaney EJ; Kaufman SJ
    Regen Med; 2007 May; 2(3):275-88. PubMed ID: 17511564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesoangioblasts of inclusion-body myositis: a twofold tool to study pathogenic mechanisms and enhance defective muscle regeneration.
    Morosetti R; Gliubizzi C; Broccolini A; Sancricca C; Mirabella M
    Acta Myol; 2011 Jun; 30(1):24-8. PubMed ID: 21842589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive monitoring of gene correction in dystrophic muscle.
    Walter G; Cordier L; Bloy D; Sweeney HL
    Magn Reson Med; 2005 Dec; 54(6):1369-76. PubMed ID: 16261578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha sarcoglycan is required for FGF-dependent myogenic progenitor cell proliferation in vitro and in vivo.
    Cassano M; Dellavalle A; Tedesco FS; Quattrocelli M; Crippa S; Ronzoni F; Salvade A; Berardi E; Torrente Y; Cossu G; Sampaolesi M
    Development; 2011 Oct; 138(20):4523-33. PubMed ID: 21903674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesoangioblasts from facioscapulohumeral muscular dystrophy display in vivo a variable myogenic ability predictable by their in vitro behavior.
    Morosetti R; Gidaro T; Broccolini A; Gliubizzi C; Sancricca C; Tonali PA; Ricci E; Mirabella M
    Cell Transplant; 2011; 20(8):1299-313. PubMed ID: 21176400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival of transplanted stem cells in immunocompetent mice with muscular dystrophy.
    Wallace GQ; Lapidos KA; Kenik JS; McNally EM
    Am J Pathol; 2008 Sep; 173(3):792-802. PubMed ID: 18711004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.